GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Solventum Corp (FRA:KB7) » Definitions » Net Income Including Noncontrolling Interests

Solventum (FRA:KB7) Net Income Including Noncontrolling Interests : €349 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Solventum Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Solventum's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was €127 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was €349 Mil.

Solventum Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Solventum's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solventum Net Income Including Noncontrolling Interests Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
935.44 1,292.10 1,267.79 1,234.28 457.45

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 218.04 82.68 109.92 29.61 126.73

Solventum Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €349 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solventum Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Solventum's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Solventum Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Solventum Corp (FRA:KB7) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ALGN HOLX ATR WST BAX COO AVTR RGEN STVN MMSI ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD TSE:4543 OCSE:COLO B XPAR:DIM XSWX:STMN
Traded in Other Exchanges
SOLV:USA KB7:Germany
Address
2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Website
https://www.solventum.com/en-us/home
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.

Solventum Headlines

No Headlines